国产av成人一区二区三区,欧美黑吊大战白妞,国产精品香蕉在线观看网

Global Biopharma Layoffs November 2025 Layoffs Layoff Novatis AbbVie Bayer Merck This article tracks recent biotech and pharma layoffs, including major workforce cuts at Novo Nordisk, Takeda, GSK, Pharming, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
Global Biopharma Layoffs October 2025 Layoffs Layoff Novo Nordisk Takeda GSK This article tracks recent biotech and pharma layoffs, including major workforce cuts at Novo Nordisk, Takeda, GSK, Pharming, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
Global Biopharma Layoffs September 2025 Layoffs Layoff Novartis Merck Novo Nordisk The biopharmaceutical industry sees major september layoffs, with companies like Novartis cutting jobs amid restructurings, trial setbacks, and M&A activity.
Henlius Biotech H1 2025 Financial Report Henlius Biotech Biotech Chinese Pharmaceutical Market Financial statements Henlius reports H1 2025 results: overseas profits soar 200%, global product expansion, and innovation pipeline growth, driving ‘Globalization 2.0’ and next-gen therapies worldwide.
Hansoh Pharma H1 2025 Financial Report Hansoh Pharma Chinese Pharmaceutical Market Financial statements Hansoh Pharma’s 2025 interim report highlights strong growth, innovation-driven transformation, and a robust global pipeline, setting a new benchmark for Chinese biopharma.
Hengrui H1 2025 Financial Report Hengrui Pharmaceuticals Hengrui Financial statements Chinese Pharmaceutical Market Hengrui Medicine’s 2025 half-year report shows 60% revenue from innovative drugs and $12B potential overseas deals, highlighting strong growth, R&D depth, and global expansion.
Rongchang Biopharma H1 2025 Financial Report Rongchang Biopharma Chinese Pharmaceutical Market Financial statements Rongchang Biopharma’s 2025 interim report shows 48% revenue growth, rising margins, reduced losses, and accelerated global BD deals, highlighting strong R&D, commercialization, and international expansion momentum.
Dizal Pharma H1 2025 Financial Report Dizal Pharma Financial statements Chinese Pharmaceutical Market Dizal Pharma reports its strongest half-year results in history, achieving first commercialization profit, accelerating R&D, and advancing global expansion with FDA-approved therapies.
Sino Biopharmaceutical H1 2025 Financial Report Sino Biopharmaceutical Financial statements Chinese Pharmaceutical Market Sino Biopharmaceutical reported RMB 17.57B revenue in 1H 2025, up 10.7%. Innovative products grew 27.2% to RMB 7.80B. R&D investment hit RMB 3.19B, with multiple new drug approvals and acquisitions.
WuXi XDC H1 2025 Financial Report WuXi XDC Financial statements Chinese Pharmaceutical Market WuXi XDC's 2025 half-year report: revenue RMB 2.701B (+62.2%), net profit RMB 746M (+52.7%), 563 global customers, 225 iCMC projects, backlog USD 1.329B, major capacity expansion in Wuxi and Singapore.